Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

GSK featured in my "Top 10" pharma social media firsts of 2013 for exceeding 90,000 Facebook 'Likes'; today, Likes on the company's page are rapidly approaching 100,000.

Shares of GSK PLC GSK inched up 0.98% to £14.39 Monday, on what proved to be an all-around positive trading session for the ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...